. Author manuscript; available in PMC: 2019 Apr 1.

Published in final edited form as: AIDS Behav. 2018 Apr;22(4):1174–1183. doi: 10.1007/s10461-017-1958-4

Table III.

Proportion of adequate adherence (at least 4 pills reported taken per week via iQS or ACASI, or DBS drug levels of 700 fmol/punch TFV or greater), by adherence method and timepoint; and discordance of adequate adherence between adherence measurement method by timepoint

		Adequate adherence N (%)	iQS Kappa (CI; p- value)	ACASI Kappa (CI; p- value)	DBS Kappa (CI; p- value)
iQS	Timepoint 1	110 (86.6)	---	0.73 (0.56–0.90; 0.10)	0.27 (0.14–0.39; <0.001^*)
iQS	Timepoint 2	61 (69.3)	---	0.71 (0.53–0.89; 0.32)	0.19 (0.04–0.34; <0.001^*)
ACASI	Timepoint 1	138 (82.6)	0.73 (0.56–0.90; 0.10)	---	0.30 (0.19–0.40; <0001^*)
ACASI	Timepoint 2	100 (74.1)	0.71 (0.53–0.89; 0.32)	---	0.27 (0.16–0.39; <0.0001^*)
DBS	Timepoint 1	73 (45.9)	0.27 (0.14–0.39; <0.001^*)	0.30 (0.19–0.40; <0001^*)	---
DBS	Timepoint 2	47 (38.8)	0.19 (0.04–0.34; <0.001^*)	0.27 (0.16–0.39; <0.0001^*)	---

p-value<0.001